Page 22 - Pharma Industry

Govt wants to ease compliance burden on pharma industry: Mandaviya

Mandaviya, who is also the Minister for Health and Family Welfare, said that the Narendra Modi-led government at the Centre is not only pro-poor and pro-farmer but "industry-friendly" as well

S&P lowers outlook for Jubilant Pharma to negative, sees weak performance

Operating performance may remain weak due to regulatory issues, says rating agency.

WPI effect: 800 key drugs likely to see 10% price rise in April

While the NPPA may allow a 10 per cent rise in prices of NLEM drugs based on WPI this year, the actual price rise could be less, say drug firms

How Indegene helps global pharma cos develop drugs faster amid Covid

Indegene uses AI and ML, and medical data mining to speed up digital transformation at top life sciences organisations

Biocon Biologics to go for IPO in 18-24 months: Kiran Mazumdar-Shaw

Biocon arm buys Viatris biosimilars biz for $3.2 billion

Make investments more attractive in pharma sector: Pre-Budget survey

A pre-budget expectations survey showed increasing demand for making investments more attractive in the pharmaceutical industry.

Domestic demand to drive pharma SMEs' growth in FY22: Crisil SME Tracker

March-May 2021 was a particularly good period for Indian formulators due to exceptional demand for drugs amid the second wave of Covid-19 infections.

Wesfarmers to buy Australia's API for $547 mn after Woolworths backs out

The news sent API's shares tumbling 12.7% to A$1.51 in early trade, as Wesfarmers' A$1.55 per share offer was 20 cents a share lower than Woolworths' proposal.

Indian pharma industry estimated to grow 9-11% in 2021-22: ICRA

The Indian pharma industry is estimated to grow at 9-11% in 2021-22 and in the next few quarters, it will be driven by domestic and emerging markets, according to ratings agency ICRA

2021 saw greater collaboration among pharma, govt, academia: Sudarshan Jain

'Diversified supply chain is a fundamental need', said Jain

Amid Covid, Pharma, healthcare industry looks to sustain momentum next year

Having proved its prowess to the world during the challenging times of the pandemic by supplying 60 per cent of the global COVID-19 vaccine requirements, the Indian pharma and healthcare industry is looking to build on the experience of the last two years, strengthen the partnership with the government and sustain the momentum in 2022. Organisation of Pharmaceutical Producers of India (OPPI) Director-General K G Ananthakrishnan told PTI that it is crucial for the industry to further build momentum towards the gains secured over the course of the pandemic which will help it carve a niche in the global pharma value chain. To this end, the industry must collectively work towards supporting, recognising, and rewarding high-risk research and development, he added. "Encouraging private sector investment in R&D and rewarding innovations through a strong intellectual property ecosystem along with the on-ground execution of the government's vision of Discover in India will spur the growth

Indian Covid vaccine makers bank on boosters as demand crashes

The SII, the world's biggest vaccine maker, and Sputnik's India distributor, Dr. Reddy's Labs, have both said they have approached health authorities about boosters

ACG to invest Rs 600 cr to build Asia's largest capsule plant in Maha

Global pharma industry supplier ACG on Tuesday said it will invest Rs 600 crore to build Asia's largest capsules manufacturing unit near Aurangabad in Maharashtra.

What ails Indian pharmaceutical space? Here's what CCI says

Cardiac medicines accounted for the highest volumes in 2020. Despite the burden of diabetes rising, its share in volumes was low; however, its share in total value was higher

Johnson & Johnson plans to split into two companies

Johnson & Johnson is splitting into two companies, separating the division that sells Band-Aids and Listerine, from its medical device and prescription drug business. The company selling prescription drugs and medical devices will keep Johnson & Johnson as its name, the company said Friday. The new consumer health company will house brands including Neutrogena, Aveeno, Tylenol, Listerine, Johnson's, and Band-Aid. A name was not disclosed for the new company. Details are sparse, but the company expect the split to occur in the next two years. The announcement comes just days after General Electric said that it plans to split into three separate companies.

With Molnupiravir, India to get affordable weapon against Covid

With six Indian pharma companies working to manufacture antiviral pill Molnupiravir, healthcare experts say the game-changing drug will give India an effective and affordable weapon

Leading drug makers Sun Pharma, Lupin recall products in US market

According to USFDA, the Mumbai-based drug maker is recalling the affected lot due to "failed moisture limits."

Novartis cuts uneasy 20-year ties to Roche with $20.7-bn voting stake sale

The company is booking a capital gain of about $14 billion on the investment at a time when the cost of acquisitions in pharma have been soaring

Sun Pharma stock expected to keep market lead as firm recovers in US

Stock trading at the highest discount to ten-year valuation averages, as brokerages favour its US specialty portfolio.

DRL steps up Sputnik V supplies with second dose from Panacea Biotec

Hospital industry sources claim they want assurance on shelf life of imported vaccines